A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer

Study Overview
=================
Brief Summary
-----------------
This is a multicenter, open-label, single-arm, phase Ib study to evaluate the safety and efficacy of Mitoxantrone Hydrochloride Liposome in subjects with Platinum-Resistant or Platinum-Refractory Relapsed Ovarian Cancer.

Detailed Description
-----------------
This is a multicenter, open-label, single-arm, phase Ib study to evaluate the safety and efficacy of Mitoxantrone Hydrochloride Liposome in subjects with Platinum-Resistant or Platinum-Refractory Relapsed Ovarian Cancer. At least 30 subjects will be recruited in this study. The subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2 by an intravenous infusion (IV), every 21 days (q3w, 1 cycle). All patients will receive the treatment until disease progression, intolerable toxic reaction, death, or withdrawal by investigator or patient decision (a maximum of 8 cycles). Delays in drug administration is allowed from the cycle 2, however, the delays should be no more than 3 weeks. Dose adjustments after the cycle 2 is permitted, and the minimum dose is 12mg/m2.

Official Title
-----------------
A Multicenter, Open-label, Single-arm, Phase Ib Study to Evaluate the Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Platinum-Resistant or Platinum-Refractory Relapsed Ovarian Cancer

Conditions
-----------------
Platinum-resistant Ovarian Cancer

Intervention / Treatment
-----------------
* Drug: Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects fully understand and voluntarily participate in this study and sign informed consent; Age ≥18, female; Histologically confirmed diagnosis of epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinoma (excluding low grade serous carcinoma and mucous carcinoma); Fail to respond to or progressed on the standard platinum-based therapy ; At least one measurable lesion according to RECIST v1.1; ECOG performance status of 0 to 2; Life expectancy ≥ 12 weeks; AEs from the previous treatment have resolved to ≤ Grade 1 based on CTCAE (except for the toxicity without safety risk judged by the investigator, such as hair loss, hyperpigmentation); Adequate organ function; Subjects of childbearing potential must agree to use effective contraceptive measures. Female subjects must have a negative pregnancy test before enrolment; Fully comply with the protocol. Exclusion Criteria: History of allergy to mitoxantrone hydrochloride or any excipients of the study drug; Untreated or symptomatic central nervous system (CNS) metastases; Pericardial effusion with clinical symptoms History of allotransplantation; Known hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV) or other active viral infection; Serious infection or interstitial pneumonia within 1 week prior to the first dose administration; Use of other anticancer treatment within 4 weeks prior to the first dose administration; Enrolled in any other clinical trials within 4 weeks prior to the first dose administration; Major surgery within 3 months prior to the first dose administration, or have a surgical schedule during the study period; Thrombosis or thromboembolism within 6 months prior to screening; History of, or known additional malignant tumor within 3 years, except for tumors have been cured and have not recurred, and carcinoma in situ; Impaired cardiac function or serious cardiac disease; Previous treatment with adriamycin or other anthracyclines, and the total cumulative dose of prior adriamycin or equivalent is >350 mg/m2. Pregnant or lactating female; Serious and/or uncontrolled systemic diseases; Not suitable for this study as decided by the investigator due to other reasons.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Mitoxantrone Hydrochloride Liposome Injection<br>Subjects with Platinum-Resistant or Platinum-Refractory Relapsed Ovarian Cancer will receive 20 mg/m2 Mitoxantrone Hydrochloride Liposome every 21 days (a cycle) for a maximum of 8 cycles. | Drug: Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)<br>* All subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| adverse events (AEs) | The incidence and severity of AEs, abnormalities in physical exams, vital sign assessments, clinical laboratory assessments, ultrasonic cardiograms (UCGs) and electrocardiographs (ECGs). | from the initiation of the first dose to 28 days after the last dose，assessed up to 36 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| overall response rate (ORR) | To investigate the preliminary antitumor efficacy | From the enrollment to the final documentation of response of the last subject (assessed up to 36 months) | 
| duration of response (DoR) | To investigate the preliminary antitumor efficacy | From the enrollment to death, lost to follow-up, withdrawal, or study end, whichever occurred first, assessed up to 36 months | 
| duration of complete response (DCR) | To investigate the preliminary antitumor efficacy | From the enrollment to death, lost to follow-up, withdrawal, or study end, whichever occurred first, assessed up to 36 months | 
| progression-free survival (PFS) | To investigate the preliminary antitumor efficacy | From the enrollment to death, lost to follow-up, withdrawal, or study end, whichever occurred first, assessed up to 36 months | 
| overall survival (OS) | To investigate the preliminary antitumor efficacy | From the enrollment to the death of last subject or the end of the clinical trial (assessed up to 36 months) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
platinum-refractory, platinum-resistant, ovarian cancer